Saskatchewan Immunization Manual Amendments October 2021

<u>Instructions</u>: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section.

Chapter 5 Immunization Schedules

- P. 11 Section 2.1 Min. Intervals for Specific Vaccine Series
 - IPV minimum age corrected to 6 weeks, from 6 months.
 - Bexsero scheduling revised as per most recent product monograph recommendation for series and ages (6 weeks to 11 months; 12-23 months; 2 years and older).

Chapter 9 – Management of Biological Products

- <u>TOC</u> page 2
 - \circ $\;$ Section 5.6 title revised to Vaccine Supply Problem report form.
 - Page numbers 35-38 amended to accommodate section 5.6.
- P. 27 section 5.2 Cold chain Break Report Form
 - Revised form added to chapter.
- <u>P. 29</u> Section 5.2A How to Complete the Cold Chain Break Report Form
 Opdated instructions: reported email address must be included.
- P. 30 Section 5.3 Product Wastage Form
 - Revised form added to chapter.
- P. 35 Section 5.6 Vaccine Supply Problem Report
 - o Revised form added to chapter.

Chapter 10 Biological Products

- TOC: Title change: Provision of COVID-19 Vaccine Booster Doses
- FluLaval Tetra
 - Updated product monograph link added.
- <u>AstraZeneca</u> COVISHIELD COVID-19 vaccine
 - New bullet under Schedule row: Refer to Provision of COVID-19 Vaccine Booster Doses added.
 - o Revised Health Canada statement added to reference list.
- Moderna COVID-19 vaccine
 - New bullet under Schedule row: Refer to Provision of COVID-19 Vaccine Booster Doses added.
 - o Revised Health Canada statement added to reference list.
 - \circ Updated product monograph date.
- <u>Pfizer</u> COVID-19 vaccine
 - New bullet under Schedule row: Refer to Provision of COVID-19 Vaccine Booster Doses added.
 - \circ $\;$ Revised Health Canada statement added to reference list
 - $\circ \quad \text{Updated product monograph date.}$
- <u>Provision of COVID-19 Vaccine Booster Doses</u>
 - o Revised title
- Bexsero
 - Under row DOSE/SERIES AND REINFORCE-MENT RECOMMENDATIONS BASED ON AGE AT PRESENTATION for those with medical risk factors, second section: age 6 months revised to 6 weeks to match product monograph recommendations.
- Varicella (Varilrix and Varivax)
 - Dose section expanded to be dose/series of two doses of 0.5 mL SC given a minimum of 28 days apart has been added.
- Priorix-Tetra
 - \circ $\;$ Latex removed from contraindication as vaccine is latex-free.